ArticleGenes & development2024
Haploinsufficiency of phosphodiesterase 10A activates PI3K/AKT signaling independent of PTEN to induce an aggressive glioma phenotype.
Open access · diamondAbstract read
In one paragraph
Article in Genes & development, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 4 citations in OpenAlex.
- Developing a Phosphodiesterase 10A Inhibitor as a Novel Therapeutic Agent for Triple-Negative Breast Cancer.Cells · 2026Article
- Loss of PDE10A is associated with metastasis of colon adenocarcinoma.Histology and histopathology · 2026Article
- Akt/mTOR pathway-mediated CCNA1 regulation of radiotherapy resistance in nasopharyngeal carcinoma.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- Isorhamnetin from Astragalus membranaceus exerts anti-glioma effects via PI3K/Akt signaling pathway.American journal of cancer research · 2026Article
- Oligosarcoma uniformly exhibits a HOX gene family hypermethylation signature.Acta neuropathologica · 2025Article
- PDE10A as a novel diagnostic and therapeutic target in cancer: insights and challenges.Frontiers in oncology · 2025Review
- HOXD12 defines an age-related aggressive subtype of oligodendroglioma.Acta neuropathologica · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 7 institutions in 2 countries.
Nicholas NuechterleinNeuropathology Unit, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20814, USA.
Allison ShelbournNeuropathology Unit, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20814, USA.
Frank SzulzewskyHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, Washington 98109, USA.
Sonali AroraHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, Washington 98109, USA.
Michelle CasadDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington 98195, USA.
Siobhan PattwellBen Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, Washington 98145, USA.
Leyre Merino-GalanBen Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, Washington 98145, USA.
Erik SulmanDepartment of Radiation Oncology, New York University Grossman School of Medicine, New York, New York 11220, USA.ORCID 0000-0003-4933-9120
Sumaita ArowaNeuropathology Unit, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20814, USA.
Neriah AlvinezNeuropathology Unit, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20814, USA.
Miyeon JungNeurosurgical Oncology Unit, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20814, USA.
Desmond BrownNeurosurgical Oncology Unit, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20814, USA.
Kayen TangDevelopmental Therapeutics and Pharmacology Unit, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20814, USA.
Sadhana JacksonDevelopmental Therapeutics and Pharmacology Unit, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20814, USA.
Stefan StoicaNeurosurgery Unit for Pituitary and Inheritable Diseases, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20814, USA.
Prashant ChittaboinaNeurosurgery Unit for Pituitary and Inheritable Diseases, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20814, USA.ORCID 0000-0001-9349-4756
Yeshavanth K Banasavadi-SiddegowdaMolecular and Therapeutics Unit, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20814, USA.
Hans-Georg WirschingDepartment of Neurology, University Hospital, University of Zurich, Zurich 8091, Switzerland.
Nephi StellaDepartment of Pharmacology, University of Washington, Seattle, Washington 98195, USA.
Linda ShapiroPaul G. Allen School of Computer Science and Engineering, University of Washington, Seattle, Washington 98195, USA.
Patrick PaddisonHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, Washington 98109, USA.
Anoop P PatelDepartment of Neurosurgery, Preston Robert Tisch Brain Tumor Center, Duke University, Durham, North Carolina 27710, USA.
Mark R GilbertNeuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20814, USA.
Zied AbdullaevLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20814, USA.ORCID 0000-0001-6345-2088
Kenneth AldapeLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20814, USA.
Drew PrattLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20814, USA.
Eric C HollandHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, Washington 98109, USA.
Patrick J CiminoNeuropathology Unit, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20814, USA; pj.cimino@nih.gov.ORCID 0000-0003-0441-4502
National Institutes of Health · USFred Hutch Cancer Center · USUniversity of Washington · USSeattle Children's Hospital · USDuke University · USNew York University · USUniversity of Zurich · CH
Funding
The role and mechanism of alternative RNA splice variants and gene fusions as drivers of cancerR35CA253119 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric C. Holland · 2021 to 2026
$6.5MIdentifying New Glioma-Associated Tumor Suppressors OncogenesZIABC011647 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI GILBERT, MARK · 2015 to 2024
$4.2MDefining cellular states of quiescence in human brain tumorsR01NS119650 · NINDS · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PADDISON, PATRICK · 2021 to 2025
$2.6MDNA methylation-based machine classification of cancerZIABC012117 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI PRATT, DREW · 2022 to 2025
$2.3MCHARACTERIZING AGGRESSIVE GLIOMA COPY NUMBER SUBTYPESK08CA245037 · NCI · UNIVERSITY OF WASHINGTON · PI CIMINO, PATRICK J. · 2020 to 2021
$512kNCI NIH HHS K08 CA245037NCI NIH HHS R35 CA253119NINDS NIH HHS R01 NS119650
Abstract
Glioblastoma is universally fatal and characterized by frequent chromosomal copy number alterations harboring oncogenes and tumor suppressors. In this study, we analyzed exome-wide human glioblastoma copy number data and found that cytoband 6q27 is an independent poor prognostic marker in multiple data sets. We then combined CRISPR-Cas9 data, human spatial transcriptomic data, and human and mouse RNA sequencing data to nominate
Indexed as
Brain NeoplasmsGlioblastomaGliomaAnimalsCell Line, TumorHaploinsufficiencyHumansMicePhosphatidylinositol 3-KinasesPhosphoric Diester HydrolasesProto-Oncogene Proteins c-aktPTEN PhosphohydrolasePDE10A protein, humanPhosphatidylinositol 3-KinasesPhosphoric Diester HydrolasesProto-Oncogene Proteins c-aktPTEN PhosphohydrolasePTEN protein, humanglioblastomamesenchymal cell statePDE10API3K/ATK pathwayRCAS/tv-a
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.